Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The complement system plays a paradoxical role in the development and expression of autoimmunity in humans. The activation of complement in systemic lupus erythematosus (SLE) contributes to tissue injury. In contrast, inherited deficiency of classical pathway components, particularly C1q (ref. 1), is powerfully associated with the development of SLE. This leads to the hypothesis that a physiological action of the early part of the classical pathway protects against the development of SLE (ref. 2) and implies that C1q may play a key role in this respect. C1q-deficient (C1qa-/-) mice were generated by gene targeting and monitored for eight months. C1qa-/- mice had increased mortality and higher titres of autoantibodies, compared with strain-matched controls. Of the C1qa-/- mice, 25% had glomerulonephritis with immune deposits and multiple apoptotic cell bodies. Among mice without glomerulonephritis, there were significantly greater numbers of glomerular apoptotic bodies in C1q-deficient mice compared with controls. The phenotype associated with C1q deficiency was modified by background genes. These findings are compatible with the hypothesis that C1q deficiency causes autoimmunity by impairment of the clearance of apoptotic cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Casciola-Rosen, L. A., Anhalt, G., & Rosen, A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.4.1317 · Cited by 1,717
Korb, L. C., & Ahearn, J. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.10.4525 · Cited by 657
Casciola-Rosen, L., Rosen, A., Petri, M., & Schlissel, M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1624 · Cited by 482
Baker, A. J., Mooney, A., Hughes, J., Lombardi, D., Johnson, R. J., & Savill, J. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117565 · Cited by 404
LeFeber, W. P., Norris, D. A., Ryan, S. R., Huff, J. C., Lee, L. A., Kubo, M., Boyce, S. T., Kotzin, B. L., & Weston, W. L. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111569 · Cited by 335
Complement deficiency and disease
Morgan, B. P., & Walport, M. J. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90003-c · Cited by 302
Self-citationNovel packages of viral and self-antigens are generated during apoptosis.
Rosen, A., Casciola-Rosen, L., & Ahearn, J. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.4.1557 · Cited by 246
Hereditary C1q deficiency and systemic lupus erythematosus
(1994) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068955 · Cited by 207
Self-citationGolan, T. D., Elkon, K. B., Gharavi, A. E., & Krueger, J. G. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115922 · Cited by 165
Subnucleosome structures as substrates in enzyme-linked immunosorbent assays
Burlingame, R. W., & Rubin, R. L. (1990) · Journal of Immunological Methods · doi:10.1016/0022-1759(90)90380-e · Cited by 124
Cited by
Items 401–500 of 1,000
Clearance of Apoptotic Photoreceptors
Hisatomi, T., Sakamoto, T., Sonoda, K., Tsutsumi, C., Qiao, H., Enaida, H., Yamanaka, I., Kubota, T., Ishibashi, T., Kura, S., et al. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64321-0 · Cited by 94
Complement C4 Is Protective for Lupus Disease Independent of C3
Einav, S., Pozdnyakova, O. O., Ma, M., & Carroll, M. C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1036 · Cited by 96
“The first is based on the hypothesis that complement plays a substantial role in the clearance of immune complexes and/or apoptotic debris (8, 9), which is thought to be impaired in lupus.”
BackgroundInfluentialThe C4b-binding Protein-Protein S Complex Inhibits the Phagocytosis of Apoptotic Cells
Kask, L., Trouw, L. A., Dahlbäck, B., & Blom, A. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400159200 · Cited by 94
Antibodies against C1q in patients with systemic lupus erythematosus
Trendelenburg, M. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-005-0007-y · Cited by 94
“to be involved in the clearance of self-antigens generated during apoptosis [6, 30, 33, 49].”
BackgroundIlyas, R., Wallis, R., Soilleux, E. J., Townsend, P. A., Zehnder, D., Tan, B. K., Sim, R. B., Lehnert, H., Randeva, H. S., & Mitchell, D. A. (2010) · Immunobiology · doi:10.1016/j.imbio.2010.06.002 · Cited by 102
“Impaired handling of apoptotic cells by complement proteins such as C1q has been shown to enhance or predispose to chronic inflammatory autoimmune diseases (31, 32), and whilst MBL deficiency may not contribute substantially to the breaking of immunological tolerance, the absence of adequate functional MBL may contrib…”
BackgroundFundamental role of C1q in autoimmunity and inflammation
Son, M., Diamond, B., & Santiago‐Schwarz, F. (2015) · Immunologic Research · doi:10.1007/s12026-015-8705-6 · Cited by 94
“contributing to the development of SLE are the following: (1) impaired apoptotic cell clearance [46] consistent with”
B Cell Subsets Contribute to Renal Injury and Renal Protection after Ischemia/Reperfusion
Renner, B., Strassheim, D., Amura, C. R., Kulik, L. N., Ljubanović, D. G., Glogowska, M. J., Takahashi, K., Carroll, M. C., Holers, V. M., & Thurman, J. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903239 · Cited by 98
Santiago‐Raber, M., Laporte, C., Reininger, L., & Izui, S. (2003) · Autoimmunity Reviews · doi:10.1016/s1568-9972(03)00062-4 · Cited by 93
GENETICS OF SYSTEMIC LUPUS ERYTHEMATOSUS
Sullivan, K. E. (2000) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70137-x · Cited by 114
Böttcher, A., Gaipl, U. S., Fürnrohr, B. G., Herrmann, M., Girkontaite, I., Kalden, J. R., & Voll, R. E. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21660 · Cited by 93
The Ro 60�kDa autoantigen: insights into cellular function and role in autoimmunity
Chen, X., & Wolin, S. L. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0529-0 · Cited by 93
“These include mutations in the complement protein C1q and the receptor tyrosine kinase Mer, both of which are involved in removing apoptotic cell debris, as well as mutations in DNase I, the enzyme that digests DNA released during cell death [68, 69, 70].”
BackgroundScott-Hewitt, N., Mahoney, M., Huang, Y., Korte, N., Yvanka de Soysa, T., Wilton, D. K., Knorr, E., Mastro, K., Chang, A., Zhang, A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.058 · Cited by 85
Triggers for anti-chromatin autoantibody production in SLE
Dieker, J. W. C., van der Vlag, J., & Berden, J. H. M. (2002) · Lupus · doi:10.1191/0961203302lu307rr · Cited by 95
Yin and Yang: complement activation and regulation in Alzheimer’s disease
Shen, Y., & Meri, S. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.08.001 · Cited by 102
Apoptosis, subcellular particles, and autoimmunity
Cline, A. M., & Radic, M. Z. (2004) · Clinical Immunology · doi:10.1016/j.clim.2004.02.017 · Cited by 99
Apoptotic Thymocyte Clearance in Scavenger Receptor Class A-Deficient Mice Is Apparently Normal
Platt, N., Suzuki, H., Kodama, T., & Gordon, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4861 · Cited by 92
“C1q-deficient mice accumulate apoptotic neutrophils in the kidney (40).”
BackgroundGenetics of Systemic Autoimmunity in Mouse Models of Lupus
Kono, D. H., & Theofilopouuos, A. N. (2000) · International Reviews of Immunology · doi:10.3109/08830180009055504 · Cited by 92
Emerging roles of TLR7 and TLR9 in murine SLE
Santiago-Raber, M.-L., Baudino, L., & Izui, S. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.10.001 · Cited by 89
Endogenous lipid mediators in the resolution of airway inflammation
Haworth, O., & Levy, B. D. (2007) · European Respiratory Journal · doi:10.1183/09031936.00005807 · Cited by 88
Do Inflammatory Cells Participate in Mammary Gland Involution?
Monks, J., Geske, F. J., Lehman, L. A., & Fadok, V. A. (2002) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1020351919634 · Cited by 107
Microglia, Alzheimer's Disease, and Complement
Crehan, H., Hardy, J., & Pocock, J. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/983640 · Cited by 84
C1q-Deficiency Is Neuroprotective Against Hypoxic-Ischemic Brain Injury in Neonatal Mice
Ten, V. S., Sosunov, S. A., Mazer, S. P., Stark, R. I., Caspersen, C., Sughrue, M. E., Botto, M., Connolly, E. S., & Pinsky, D. J. (2005) · Stroke · doi:10.1161/01.str.0000182237.20807.d0 · Cited by 87
Self-citationAccelerated Nephrotoxic Nephritis Is Exacerbated in C1q-Deficient Mice
Robson, M. G., Cook, H. T., Botto, M., Taylor, P. R., Busso, N., Salvi, R., Pusey, C. D., Walport, M. J., & Davies, K. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6820 · Cited by 90
Self-citationComplement and microglia dependent synapse elimination in brain development
Soteros, B. M., & Sia, G.-M. (2021) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1545 · Cited by 101
Uehara, H., & Shacter, E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2522 · Cited by 87
“Studies using gene knockout mice have shown an association between autoimmune disease and abnormal clearance of apoptotic cells (7, 8).”
BackgroundKono, D. H., & Theofilopoulos, A. N. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0030-7 · Cited by 97
Tian, J., Xu, Z., Smith, J. S., Hofherr, S. E., Barry, M. A., & Byrnes, A. P. (2009) · Journal of Virology · doi:10.1128/jvi.00082-09 · Cited by 88
“the classical pathway (5) to definitively determine whether the”
BackgroundMethodCheng, M., & Anderson, M. S. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074953 · Cited by 93
“Like patients with hereditary Clq deficiency, C1qa−/−mice develop features of SLE, chiefly high-titer ANAs and glomerulonephritis with IC deposition within the kidneys (16).”
BackgroundClearing the way to mechanisms of autoimmunity
Rosen, A., & Casciola-Rosen, L. A. (2001) · Nature Medicine · doi:10.1038/89034 · Cited by 89
Todt, J. C., Hu, B., & Curtis, J. L. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0903439 · Cited by 86
“Redundancy in the pathways mediating apoptotic cell clearance has been noted previously [4], and with the notable exception of mice lacking C1q [57], gene-targeting of receptors clearly involved in apoptotic cell recognition does not invariably lead to apoptotic cell accumulation [58].”
BackgroundLinking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus
Giles, B. M., & Boackle, S. A. (2012) · Immunologic Research · doi:10.1007/s12026-012-8345-z · Cited by 96
“The importance of this process has been demonstrated in C1q-deficient mice, in which apoptotic debris is not efficiently cleared and *25 % develop glomerulonephritis associated with multiple apoptotic bodies [106].”
Erdei, A., Isaák, A., Török, K., Sándor, N., Kremlitzka, M., Prechl, J., & Bajtay, Z. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.05.181 · Cited by 99
Fadok, V. A., Xue, D., & Henson, P. M. (2001) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400856 · Cited by 88
Phagocytosis of apoptotic cells by liver: A morphological study
Dini, L., Pagliara, P., & Carlà, E. C. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10107 · Cited by 87
“…manipulation of phagocyte responses to apoptotic cell stimuli and the development of novel therapeutic strategies (for example, during tissue repair) as an effective antiinflammatory and immunosuppressive strategy (Voll et al., 1997; Fadok et al., 1998; Botto et al., 1998; Herrmann et al., 1998).”
Complement Therapeutics in Autoimmune Disease
Thurman, J. M., & Yapa, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00672 · Cited by 93
“Mice with targeted deletion of the C1qa gene have a greater abundance of apoptotic bodies in the kidney than control mice, and they develop auto-antibodies to nuclear antigens (22).”
BackgroundAger, R. R., Fonseca, M. I., Chu, S., Sanderson, S. D., Taylor, S. M., Woodruff, T. M., & Tenner, A. J. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06595.x · Cited by 86
“…C1q alone has been demonstrated to have multiple effects in other disease states, including the ability to enhance phagocytosis of apoptotic cells (Botto et al. 1998) and suppress proinflammatory cytokines (Fraser et al. 2009) and the ability to provide direct protection to injured neurons…”
BackgroundEggleton, P., Tenner, A. J., & Reid, K. B. M. (2001) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2000.01218.x · Cited by 86
Rovere, P. Q., Sabbadini, M. G., Fazzini, F., Bondanza, A., Zimmermann, V. S., Rugarli, C., & Manfredi, A. A. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200008)43:8<1663::aid-anr1>3.0.co;2-1 · Cited by 91
Lagumersindez-Denis, N., Wrzos, C., Mack, M., Winkler, A., van der Meer, F., Reinert, M. C., Hollasch, H., Flach, A., Brühl, H., Cullen, E., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1706-x · Cited by 80
“2D2 mice (TCR) [6], Th/+mice (IgG, kindly provided by Tobias Litzenburger, Antonio Iglesias and Hartmut Wekerle [31]), OSE double transgenic mice (TCR × IgG) [5, 26], RAG1−/− mice [37], RAG2−/− γc−/−, RAG1−/− γc, C1q−/− (kindly provided by Marina Botto [8]) and OT-II [4] mice were bred at the animal facility of the Un…”
MethodHamada, M., Tsunakawa, Y., Jeon, H., Yadav, M. K., & Takahashi, S. (2019) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.19-0076 · Cited by 90
“C1q is the first protein involved in the complement component classical pathway, and its deficiency causes autoimmune disease in both humans and mice [6, 68].”
BackgroundImmune modulation of human dendritic cells by complement
Castellano, G., Woltman, A. M., Schlagwein, N., Xu, W., Schena, F. P., Daha, M. R., & van Kooten, C. (2007) · European Journal of Immunology · doi:10.1002/eji.200636845 · Cited by 93
Complement, interferon and lupus
Elkon, K. B., & Santer, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.08.004 · Cited by 91
Complement deficiencies in humans and animals: Links to autoimmunity
Lewis, M. J., & Botto, M. (2006) · Autoimmunity · doi:10.1080/08916930600739233 · Cited by 82
“C1q-deficient mice on a hybrid genetic background (129!C57BL/6) developed significant levels of autoantibodies in a typical lupus pattern, associated with histologically proven glomerulonephritis [53].”
BackgroundSelf-citationGalvan, M. D., Luchetti, S., Burgos, A. M., Nguyen, H. X., Hooshmand, M. J., Hamers, F. P. T., & Anderson, A. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2823-08.2008 · Cited by 81
“C1q KO mice on a mixed C57BL/6 background were generously provided by Andrea Tenner with permission by Marina Botto (Botto et al., 1998).”
MethodApoptosis in systemic lupus erythematosus
Kaplan, M. J. (2004) · Clinical Immunology · doi:10.1016/j.clim.2004.04.007 · Cited by 85
Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis
Bélot, A., & Cimaz, R. (2012) · Pediatric Rheumatology · doi:10.1186/1546-0096-10-21 · Cited by 99
“Early components of the classical pathway (especially C1q) help clearing apoptotic cells, thus decreasing the number of autoantigens [9].”
BackgroundGalvan, M. D., Foreman, D. B., Zeng, E., Tan, J. C., & Bohlson, S. S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102920 · Cited by 82
“C 1q is the recognition component of the classical complement pathway, and C1q is also required for efficient clearance of apoptotic cells (1).”
BackgroundInfluentialRheumatic syndromes associated with complement deficiency
Barilla‐LaBarca, M., & Atkinson, J. P. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200301000-00010 · Cited by 85
Rupprecht, T. A., Angele, B., Klein, M., Heesemann, J., Pfister, H.-W., Botto, M., & Koedel, U. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1861 · Cited by 82
“(28), as described previously, and then backcrossed for 10 generations onto a C57BL/6 background.”
BackgroundSelf-citationOpsonization of Apoptotic Cells and Its Effect on Macrophage and T Cell Immune Responses
Kim, S. J., Gershov, D., Ma, X., Brot, N., & Elkon, K. B. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb06034.x · Cited by 95
Mitchell, D. A., Taylor, P. R., Cook, H. T., Moss, J., Bygrave, A. E., Walport, M. J., & Botto, M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5676 · Cited by 86
Self-citationComplement: coming full circle
Friec, G. L., & Kemper, C. (2009) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-009-0047-4 · Cited by 90
“Particularly the early complement components C1, C2, C4, and MBL have been associated with early-onset SLE (Agnello et al. 1972; Botto et al. 1998; Day et al. 1973; Lewis and Botto 2006; Manderson et al. 2004; Pickering et al. 2000).”
BackgroundInfluentialOtten, M. A., van der Bij, G. J., Verbeek, S. J., Nimmerjahn, F., Ravetch, J. V., Beelen, R. H. J., van de Winkel, J. G. J., & van Egmond, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6829 · Cited by 84
“Fc RI/ III / (CD64/CD16 double KO), Fc RI/II/III / (CD64/CD32/CD16 triple KO), and C1q / (C1q KO) mice (30) were bred at the Animal Facility of the LUMC, Leiden, The Netherlands.”
BackgroundCrampton, S. P., Morawski, P. A., & Bolland, S. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.016451 · Cited by 81
“Mice deficient in C1q also develop systemic autoimmunity, characterized by kidney disease caused by glomerular deposits of apoptotic bodies (Botto et al., 1998).”
Waggoner, S. N., Cruise, M. W., Kassel, R., & Hahn, Y. S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4706 · Cited by 80
“Although the physiologic role of gC1qR in the immune response remains to be established, natural C1q deficiency in humans (7, 8) as well as targeted deletion in mice (9) have identified a role for this ligand in immune regulation and prevention of autoimmune disease.”
BackgroundJaillon, S., Jeannin, P., Hamon, Y., Frémaux, I., Doni, A., Bottazzi, B., Blanchard, S., Subra, J., Chevailler, A., Mantovani, A., et al. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.173 · Cited by 88
Sekine, H., Kinser, T. T. H., Qiao, F., Martinez, E., Paulling, E. E., Ruiz, P., Gilkeson, G. S., & Tomlinson, S. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30222 · Cited by 87
“Mice deficient in C1q have increased mortality and higher titers of autoantibodies, and glomerulonephritis with glomerular IC deposits and multiple apoptotic bodies develop in 25% of C1q-deficient mice (7).”
BackgroundComplement activation and diabetic vascular complications
Østergaard, J. A., Hansen, T. K., Thiel, S., & Flyvbjerg, A. (2005) · Clinica Chimica Acta · doi:10.1016/j.cccn.2005.04.028 · Cited by 85
Bijl, M., Horst, G., Bijzet, J., Bootsma, H., Limburg, P. C., & Kallenberg, C. G. M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10737 · Cited by 83
Autoimmunity versus tolerance: Can dying cells tip the balance?
Viorritto, I. C. B., Nikolov, N. P., & Siegel, R. M. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.07.012 · Cited by 92
“[45,46] One proposed mechanism of uptake via C1q is through interaction with CD91 on the phagocyte.”
BackgroundSpivia, W. R., Magno, P. S., Le, P., & Fraser, D. A. (2014) · Inflammation Research · doi:10.1007/s00011-014-0762-0 · Cited by 85
“C1q’s protective role in the autoimmune disease is well described [25].”
Innate immunity and brain inflammation: the key role of complement
Francis, K., van Beek, J., Canova, C., Neal, J. W., & Gasque, P. (2003) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399403006252 · Cited by 80
Autoantibodies against Complement C1q Specifically Target C1q Bound on Early Apoptotic Cells
Bigler, C., Schaller, M. M., Perahud, I., Osthoff, M. F., & Trendelenburg, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803573 · Cited by 82
“Because C1q-deficient mice developed a lupus-like disease with accumulation of apoptotic bodies in the glomeruli, but not in other organs (53), one can speculate that glomeruli are particularly sensitive to defects in the clearance of apoptotic cells, and therefore might be the loci of predilection for the mechanisms…”
Maeda, Y., Shiratsuchi, A., Namiki, M., & Nakanishi, Y. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401046 · Cited by 82
Role of Cyclin Kinase Inhibitor p21 in Systemic Autoimmunity
Santiago-Raber, M.-L., Lawson, B. R., Dummer, W., Barnhouse, M., Koundouris, S., Wilson, C. B., Kono, D. H., & Theofilopoulos, A. N. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.7.4067 · Cited by 83
“the 129/Sv C57BL/6, one records low degrees of antinuclear immunity and mild immune deposits at advanced age (35, 36).”
BackgroundComplement in Alzheimer's disease: opportunities for modulating protective and pathogenic events
Tenner, A. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00301-3 · Cited by 81
Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models
Pathak, S., & Mohan, C. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3465 · Cited by 85
“and develop proliferative glomerulonephritis characterized by high levels of apoptotic cell bodies [9].”
BackgroundJacob, N., Guo, S., Mathian, A., Koss, M. N., Gindea, S., Putterman, C., Jacob, C. O., & Stohl, W. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000466 · Cited by 81
Qian, Y., Wang, H., & Clarke, S. H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.625 · Cited by 81
“C1q-deficient mice have a marked accumulation of apoptotic cells in the kidney (17) and C1q deficiency also leads to the development of a severe lupus-like disease in both humans and mice (18).”
C1q and C4b Bind Simultaneously to CR1 and Additively Support Erythrocyte Adhesion
Tas, S. W., Klickstein, L. B., Barbashov, S. F., & Nicholson-Weller, A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.5056 · Cited by 81
“Recent experiments in knockout mice confirmed a role for C1q in preventing autoimmunity (18).”
BackgroundFeng, J. Q., Mozdzanowska, K., & Gerhard, W. (2002) · Journal of Virology · doi:10.1128/jvi.76.3.1369-1378.2002 · Cited by 80
Lupus Around the World: Systemic lupus erythematosus and infections: a retrospective study in Saudis
Alrayes, H., Al-Swailem, R., Arfin, M., Sobki, S. H., Rizvi, S., & Tariq, M. (2007) · Lupus · doi:10.1177/0961203307079943 · Cited by 85
Clearance: The Last and Often Forgotten Stage of Apoptosis
Fadok, V. A. (1999) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1011384009787 · Cited by 93
Mixed connective tissue disease
Hoffman, R. W., & Greidinger, E. L. (2000) · Current Opinion in Rheumatology · doi:10.1097/00002281-200009000-00006 · Cited by 80
Lillis, A. P., Greenlee, M. C., Mikhailenko, I., Pizzo, S. V., Tenner, A. J., Strickland, D. K., & Bohlson, S. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.364 · Cited by 77
“To examine the role of C1q in the serum-mediated increase in phagocytosis, we performed the same phagocytosis assay in the presence of mouse serum genetically devoid of C1q (C1q / ) (12).”
BackgroundMethodComplement System in Alzheimer’s Disease
Shah, A., Kishore, U., & Shastri, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413647 · Cited by 73
“(2004), who crossed AD mice model Tg2576 mice (APP mutation) with C1q−/− mice, giving rise to APPQ−/− mice which exhibited AD pathology but lacked C1q, and these mice were compared with APP mice [90,93,95,96].”
BackgroundContribution of Defective PS Recognition and Efferocytosis to Chronic Inflammation and Autoimmunity
Kimani, S. G., Geng, K., Kasikara, C., Kumar, S., Sriram, G., Wu, Y., & Birge, R. B. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00566 · Cited by 83
“A2, A5, and CRT Deficiency leads to auto-immune diseases (29) Ninety percent of C1q-deficient”
Novel collectin/C1q receptor mediates mast cell activation and innate immunity
Edelson, B. T., Stricker, T. P., Li, Z., Dickeson, S. K., Shepherd, V. L., Santoro, S. A., & Zutter, M. M. (2006) · Blood · doi:10.1182/blood-2005-06-2218 · Cited by 78
Expression of B Cell Receptor-Associated Signaling Molecules in Human Lupus
Huck, S., Corre, R. L., Youinou, P., & Zouali, M. (2001) · Autoimmunity · doi:10.3109/08916930109008048 · Cited by 83
Lobsiger, C. S., Boillée, S., Pozniak, C., Khan, A. M., McAlonis-Downes, M., Lewcock, J. W., & Cleveland, D. W. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318309110 · Cited by 72
“To assess if C1q induction and activation of the classic complement pathway contribute to pathogenesis, we crossbred C1q-deleted mice (42) with mutant SOD1 ALS mice (which have a typical survival of 6 mo).”
BackgroundMethodInfluentialChapman, K. E., Coutinho, A. E., Gray, M., Gilmour, J. S., Savill, J., & Seckl, J. R. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1366.030 · Cited by 89
Complement C1q-induced activation of β-catenin signalling causes hypertensive arterial remodelling
Sumida, T. S., Naito, A. T., Nomura, S., Nakagawa, A., Higo, T., Hashimoto, A., Okada, K., Sakai, T., Ito, M., Yamaguchi, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms7241 · Cited by 80
Self-citationNucleosomes in the pathogenesis of systemic lupus erythematosus
Koutouzov, S., Jerônimo, A. L. C., Campos, H., & Amoura, Z. (2004) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2004.04.001 · Cited by 77
“Mice that are deficient for C1q develop antinuclear autoantibodies and glomerulonephritis and show the presence of apoptotic bodies in the glomerulus [46].”
BackgroundApoptosis in systemic lupus erythematosus
White, S. M., & Rosen, A. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200309000-00006 · Cited by 77
Nucleic acid sensing Toll-like receptors in autoimmunity
Ewald, S. E., & Barton, G. M. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.11.006 · Cited by 82
“Mice lacking a functional copy of the complement protein C1q or the phagocytic receptor MER, cannot effectively clear apoptotic bodies, and an SLE-like disease develops characterized by ANA production [9,10].”
BackgroundAnti-DNA autoreactivity in C4-deficient mice
Paul, E., Pozdnyakova, O. O., Mitchell, E., & Carroll, M. C. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200209)32:9<2672::aid-immu2672>3.0.co;2-x · Cited by 75
Complement modulation of T cell immune responses during homeostasis and disease
Clarke, E. V., & Tenner, A. J. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.3mr0214-109r · Cited by 80
“C1qa / mouse, in vivo C1qa / , in vivo model, unclear whether direct or indirect SLE [2] C1q enhances IFN- production in antigen-dependent T cells.”
BackgroundResultInfluentialGabillet, J., Millet, A., Pederzoli-Ribeil, M., Tacnet‐Delorme, P., Guillevin, L., Mouthon, L., Frachet, P., & Witko‐Sarsat, V. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200600 · Cited by 81
“The fact that the globular domain of CRT, which recognizes PR3, is also involved in PS and C1q binding (14, 30, 31), which is critical in apoptotic cell recognition (9, 32), provides further evidence of the important functional role of the CRT–PR3 interaction.”
BackgroundInfluentialZhao, Y., Wei, W., & Liu, M. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102540 · Cited by 77
Taylor, P. R., Pickering, M. C., Kosco‐Vilbois, M. H., Walport, M. J., Botto, M., Gordon, S., & Martínez‐Pomares, L. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200207)32:7<1883::aid-immu1888>3.0.co;2-8 · Cited by 76
Self-citationGABA-receptive microglia selectively sculpt developing inhibitory circuits
Favuzzi, E., Huang, S., Saldi, G.-A., Binan, L., Ibrahim, L. A., Fernández-Otero, M., Cao, Y., Zeine, A., Sefah, A., Zheng, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.10.009 · Cited by 124
Complement Component C1q and Anti‐C1q Antibodies in Theory and in Clinical Practice
Potluková, E., & Králíková, P. (2008) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2008.02089.x · Cited by 75
Saeland, E., Vidarsson, G., Leusen, J. H. W., van Garderen, E., Nahm, M. H., Vile-Weekhout, H., Walraven, V., Stemerding, A. M., Verbeek, J. S., Rijkers, G. T., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.6158 · Cited by 73
Roumenina, L. T., Sène, D., Radanova, M., Blouin, J., Halbwachs-Mecarelli, L., Dragon-Durey, M.-A., Fridman, W. H., & Fremeaux-Bacchi, V. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101749 · Cited by 69
Zwart, B., Ciurana, C. L. F., Rensink, I., Manoe, R., Hack, C. E., & Aarden, L. A. (2004) · Autoimmunity · doi:10.1080/0891693042000196183 · Cited by 74
“in combination with the well known strong association between C1q deficiency and the development of systemic lupus erythematosus (SLE), have put forward the hypothesis that C1q deficiency could predispose to SLE because of a defect in the clearance of apoptotic cells.([16,23]) Mice deficient in C1q indeed display dist…”
BackgroundComplement's participation in acquired immunity
Nielsen, C. H., & Leslie, R. G. Q. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.2.249 · Cited by 85
“Indeed, mice deficient in C1q exhibit impaired clearance of apoptotic cells injected in vivo [171] along with increased glomerular deposition of apoptotic bodies, increased incidence of glomerulonephritis, elevated titers of autoantibodies, and increased mortality [172].”
BackgroundC1q, antibodies and anti-C1q autoantibodies
Beurskens, F. J. M., van Schaarenburg, R. A., & Trouw, L. A. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.05.010 · Cited by 83
The α2β1 integrin: A novel collectin/C1q receptor
Zutter, M. M., & Edelson, B. T. (2007) · Immunobiology · doi:10.1016/j.imbio.2006.11.013 · Cited by 83
Apoptotic cell-based therapies against transplant rejection: role of recipient’s dendritic cells
Morelli, A. E., & Larregina, A. T. (2010) · Apoptosis · doi:10.1007/s10495-010-0469-9 · Cited by 70
“Indeed, mice with deficiencies in molecules critical for recognition, internalization, or lysosomal DNA degradation of apoptotic cells, including C1q, C4, IgM, the pentraxin Serum Amyloid P, MerTK, milk fat globule protein-E8, class A scavenger receptors, or lysosomal DNase II develop systemic autoimmune disorders [60…”
BackgroundBeyond C4d: Other Complement-Related Diagnostic Approaches to Antibody-Mediated Rejection
Baldwin, W. M., Kasper, E. K., Zachary, A. A., Wasowska, B. A., & Rodríguez, E. R. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00348.x · Cited by 76
“The possibility that C4 can prevent tissue injury is supported by the fact that patients with spontaneous deficiencies and mice with genetically engineered deficiencies of C1 or C4 have severe forms of autoimmunity with accumulations of apoptotic bodies in sites of inflammation (42,43).”
Background
Metadata
- Authors
- Botto, M., Dell' Agnola, C., Bygrave, A. E., Thompson, E. M., Cook, H. T., Petry, F., Loos, M., Pandolfi, P. P., & Walport, M. J.
- Affiliations
- Imperial College London (GB)
- Institute of Medical Microbiology and Hygiene (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Walport, Mark J.
- Venue
- Nature Genetics
- Published
- 1998-05
- Volume
- 19
- Issue
- 1
- Pages
- 56-59
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2067217824
- Cited by
- 1,434
- References
- 21
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 22 · 2023: 18 · 2022: 27 · 2021: 29 · 2020: 20 · 2019: 39 · 2018: 29 · 2017: 37 · 2016: 27 · 2015: 36 · 2014: 47 · 2013: 39 · 2012: 62
- FWCI
- 49.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Keywords
- C1q deficiency, glomerulonephritis, apoptotic bodies, systemic lupus erythematosus, classical complement pathway, autoimmunity, autoantibodies, efferocytosis, genetic background effects, immune deposits
- MeSH terms
- Animals, Antibodies, Antinuclear, Autoantigens, Crosses, Genetic, Glomerulonephritis, Homozygote, Kidney Glomerulus, Microscopy, Electron, Complement C1q, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.